Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM 718 a Weekly MC4R specific Agonist

Monday, March 25, 2024 1 min read

Key Takeaway: Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM 718 a Weekly MC4R specific Agonist

Full Press Release Details

Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM 718 a Weekly MC4R specific Agonist.